Peer Reviewed

1

Document Type

Article

Publication Date

10-3-2018

Keywords

Epilepsy, prostaglandin E2, EP1 receptor, EP3 receptor, pentylenetetrazole

Funder/Sponsor

Coordination for the Improvement of Higher Education Personnel (CAPES), Brazilian Natio- nal Council for Scientific and Technological Development (CNPq) and Science Foundation Ireland (17/TIDA/5002).

Comments

The original article is available at http://www.ijcep.com/

Abstract

Neuroinflammation plays a major role in brain excitability and may contribute to the development of epilepsy. Prostaglandin E2 (PGE2) is a direct mediator of inflammatory responses and, through EP receptors, plays an important role in neuronal excitability. Pharmacological evidence supports that centrally-administered EP1 and EP3 receptor antagonists reduced acutely evoked seizures in rats. Translation of these findings would benefit from evidence of efficacy with a more clinically relevant route of delivery and validation in another species. In the current study we investigated whether the systemic administration of EP1 and EP3 agonists and antagonists modulate pentylenetetrazole (PTZ)-induced seizures in mice. In addition, it was examined whether these compounds alter Na+, K+-ATPase activity, an enzyme responsible for the homeostatic ionic equilibrium and, consequently, for the resting membrane potential in neurons. While the systemic administration of EP1 and EP3 antagonists (ONO-8713 and ONO-AE3-240, respectively) attenuated, the respective agonists (ONO-DI-004 and ONO-AE-248) potentiated PTZ-induced seizures (all compounds injected at the dose of 10 µg/kg, s.c., 30 min before PTZ challenge). Co-administration of either EP1 or EP3 agonist with the respective antagonists nullified the anticonvulsant effects of EP1/3 receptor blockade. In addition, EP1 and EP3 agonists exacerbated PTZ-induced decrease of Na+, K+-ATPase activity in both cerebral cortex and hippocampus, whereas, EP1 and EP3 antagonists prevented PTZ-induced decrease of Na+, K+-ATPase activity in both structures. Our findings support and extend evidence that EP1 and EP3 receptors may be novel targets for the development of anticonvulsant drugs.

Disciplines

Physics | Physiology

Citation

Reschke CR, Poersch AB, Masson CJ, Jesse AC, Marafiga JR, Lenz QF, Oliveira MS, Henshall DC, Mello CF. Systemic delivery of selective EP1 and EP3 receptor antagonists attenuates pentylenetetrazole-induced seizures in mice. International Journal of Physiology, Pathophysiology and Pharmacology. 2018;10(1):47-59.

PubMed ID

29593850

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS